Roche: Committed to innovation and profitable growth. Dr. Alan Hippe, CFO Roche. May 2012
|
|
- Christina Richardson
- 6 years ago
- Views:
Transcription
1 Roche: Committed to innovation and profitable growth Dr. Alan Hippe, CFO Roche May
2 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates, future or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage. Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche. For marketed products discussed in this presentation, please see full prescribing information on our website All mentioned trademarks are legally protected 2
3 A good start into the year Strong fundamentals Sustainable strategy 3
4 Q1 2012: Highlights Sales Group and Pharma: +2% 1 (+3% 1 excluding Tamiflu) Diagnostics: +4% 1 Negative currency impact (-3%p) 2 Approvals of New Molecular Entities Erivedge in advanced basal cell carcinoma approved in US Zelboraf in metastatic melanoma approved in EU 5 positive late-stage trials and regulatory filings Avastin in metastatic colorectal cancer: treatment through multiple lines (TML) T-DM1 in HER2+ metastatic breast cancer (EMILIA) Herceptin subcutaneous in HER2+ breast cancer (HANNAH)-filed in EU Actemra in polyarticular-course juvenile idiopathic arthritis (CHERISH) Actemra in rheumatoid arthritis (ADACTA) 1 at Constant Exchange Rates 4
5 Q1 2012: Group sales On track to meet full-year guidance change in % CHF m CHF m CHF CER Pharmaceuticals Division 8,624 8, Diagnostics Division 2,403 2, Roche Group 11,027 11, CER=Constant Exchange Rates 5
6 Q1 2012: Pharma sales drivers Oncology and Pegasys main growth drivers Pegasys MabThera/Rituxan Herceptin +7% +7% +32% Actemra/RoActemra Xeloda +46% +15% Zelboraf NA CellCept -19% Tamiflu Boniva/Bonviva NeoRecormon/Epogin -24% -31% -28% International US Japan Western Europe Absolute amounts in CHF m at Constant Exchange Rates (CER) average 2011; all growth rates at CER
7 Pharma quarterly growth (excluding Tamiflu),400 +3% +3%,300 +1% CHF m,200,100,0 -,100 +1% 0% US International WE Japan -,200 Q1 '11 Q2 '11 Q3 '11 Q4 '11 Q1 '12 Absolute amounts in CHF m at Constant Exchange Rates (CER) average 2011; all YOY growth rates at CER 7
8 Q1 2012: US back to strong growth Driven by Oncology and Pegasys US: +6% 2 US growth contribution 1 Growth 2 Pegasys % Rituxan 52 +8% Herceptin % Xeloda % Zelboraf 26 NA Actemra % Tarceva % 1 CHF m at average 2011 exchange rates; 2 CER=Constant Exchange Rates 8
9 Q1 2012: Western Europe Significant impact of genericized products 2, Bonviva CellCept Neorecormon Mircera Other tail products Pricing pressure MabThera RoActemra Herceptin Zelboraf Pegasys -4% 1 FX Q FX Q Sales 1 CER=Constant Exchange Rates 9
10 E7 countries: solid growth despite strong base One-off effects in Q1 in China and Russia 1000,000, +5% 1 800,000, 600,000, India Russia Korea Turkey Mexico 400,000, +15% China 200,000,,0, +19% Q1 '11 Q2 '11 Q3 '11 Q4 '11 Q1 '12 Brazil 1 CER=Constant Exchange Rates; absolute values in CHF m at average 2011 exchange rates 10
11 China: Roche outgrowing the market 35% 30% 32% 29%* 25% 20% 19% 20% 24% 17% 15% 14% 16% 16% 10% 5% 0% Roche Chinese market Q1 '11 Q2 '11 Q3 '11 Q4 '11 Q1 '12 Source: IMS Hospital Audits, January 2012; * Roche estimate for Q1 in-market sales in China 11
12 Securing growth for HER2 franchise HannaH and EMILIA advancing the standard of care 2nd line mbc Xeloda + lapatinib T-DM1 (EMILIA) 1st line mbc Herceptin + chemo Herceptin & pertuzumab + chemo (CLEOPATRA) T-DM1 & pertuzumab Adjuvant BC Herceptin + chemo Herceptin subcutaneous + chemo (HannaH) Herceptin & pertuzumab + chemo Established standard of care Potential new standard of care Future standard of care Timelines refer to the expected dates of first filing 12
13 Q2 2012: Clinical data to be presented at upcoming meetings EASL Barcelona, April danoprevir+mericitabine INFORM-SVR (phii, interferon-free combination) treatment-naive and interferon intolerant chronic HepC G1 danoprevir DAUPHINE (phii) treatment-naive chronic HepC mericitabine PROPEL, JUMP-C (phii) treatment-naive and failure chronic HepC G1/4 T-DM1 ASCO Chicago, June 1-5 EMILIA (submitted) pretreated HER2+ mbc PhII safety study in HER2+ ebc Avastin TML treatment through multiple lines in mcrc AURELIA platinum resistant ovarian cancer Actemra EULAR Berlin, June 6-9 ADACTA (submitted) Head-to-Head vs. Humira Virology Oncology Inflammation 13
14 A good start into the year Strong fundamentals Sustainable strategy 14
15 2011: Group performance Core EPS growth +11% 1 CHF m % Change CHF CER Sales 47,473 42, Core operating profit 16,591 15, as % of sales Core net financial income -2,272-1, Core tax rate in % p Core net income 11,181 10, as % of sales Attributable to Roche shareholders 10,955 10, Core EPS (CHF) Operating free cash flow 14,149 13, % of sales p Free cash flow 4,699 3, % of sales p 1 CER = Constant Exchange Rates 15
16 2011: Core operating profit development Profit growth driven by productivity improvements CHF m 16,591 US healthcare reform incl. excise tax EU austerity measures Japan price cuts % -609 Tamiflu Avastin US/WE CellCept US/WE Boniva US/WE sales +1,764* +1,037 Profit growth underlying business 1 17,643 Core Operating Profit ,140 Cost savings Operational Excellence Core Operating Profit FY10 Fx FY10 Fx rates * corresponds to CHF 1,836 m at exchange rates at the time of Operational Excellence announcement; 1 including Genentech integration synergies 16
17 Continuous growth in operating profit and margin Group core operating profit (CHF bn) and margin 33.0% 33.2% 34.9% 35.6% +6% in CER CER = constant exchange rates
18 Continuous increase in dividends and pay-out ratio Average yearly dividend growth ( ): 19% Payout Ratio of 55.3% 3.40 CHF Pay-out compound ratio calculated annual growth as dividend rate per share divided by core earnings per share (diluted); 2011 as proposed by the Board of Directors 18
19 Debt maturity profile Q Evolution CHF bn Repayment of CHF 2.2bn at maturity Tender of EUR 782m Repayments in Q1/2012 Refinancing in Q1/ USD EUR CHF GBP Of the CHF 48.2bn bonds and notes issued to finance the Genentech transaction, cumulative 23.6bn (49%) have been repaid as of 31 Mar 2012 * Nominal actual FX rates; *Original net proceeds in CHF 19
20 A good start into the year Strong fundamentals Sustainable strategy 20
21 Roche: Focused on medically differentiated therapies Focus Pharma Dia Premium for innovation Generics OTC MedTech Differentiation 21
22 P&L structure reflecting innovation based strategy Peer group core operating profit margin 2011 Eli Lilly Roche Merck Novartis Astra Sanofi GSK Pfizer JNJ R&D % sales 21% 19% 17% 16% 15% 14% 14% 13% 12% Pfizer Astra Roche Sanofi Merck Core operating profit margin % sales 36% 34% 34% 39% 43% Eli Lilly Novartis JNJ Pfizer Merck GSK Astra Sanofi Roche M&D+G&A % sales 33% 32% 30% 29% 29% 29% 28% 24% 23% GSK JNJ Novartis Eli Lilly 27% 27% 27% 31% 22
23 R&D productivity Excellence in science key lever to reduce attrition Industry success rate Research Phase 0 Phase 1 Phase 2 Phase 3 RegistrationLaunch Understanding of disease biology Probability of success - 64% 48% 25% 67% 83% 4% Leveraging Personalized Healthcare - stratify patient population early on Industry: 4% Roche: 9% Rigorous decision making transition only most promising projects Major decision points Source: Industry success rates - Linda Martin, KMR, Bernstein R&D conference 2011 Roche publically available data, BCG analysis 23
24 Personalised Healthcare is a reality today Significant progress in 2011 APPROVED FILED TO FILE IN 2012 Zelboraf Metastatic Melanoma BRAF V600E Mutation Pertuzumab Metastatic Breast Cancer HER2 expression level T-DM1 Metastatic Breast Cancer HER2 expression level Ph III Ph III Ph III decision in 2012 MetMAb NSCLC Met Status Lebrikizumab Severe uncontrolled asthma Periostin level Mericitabine and danoprevir Hepatitis C HCV viral load, genotype 24
25 Roche Diagnostics commitment to PHC Preferred Partner for Companion Diagnostics (CDx) Internal collaborations > External collaborations 1 Personalized Healthcare collaborations with more than 30 pharma and biotech companies Tissue Diagnostics signs 4 new partnerships - Pfizer (Crizotinib ALK IHC) - Syndax (Entinostat- E-cadherin) - Aeterna Zentaris (AEZS 108 LHRH) - Bayer (antibody-drug conjugate) 1 Including R&D collaborations and CDx projects 25
26 Roche strategy for post-patent biologics marketplace Actively pursuing multiple strategies Innovate Re-define the standard of care Mode of administration, combination therapies and new drugs Protect Protect high standards Enforce efficacy and safety standards, defend intellectual property Expand Act to expand patient access in emerging markets Change from global pricing to tiered pricing, including 2nd brand 26
27 Filings and launches in 2012 New Molecular Entities Zelboraf met. melanoma Erivedge (US) adv. basal cell carcinoma pertuzumab HER2+ mbc 1st line T-DM1 HER2+ advanced mbc Launches Filed/awaiting launch Planned filings Additional indications Oncology Immunology CardioMetabolism Avastin relapsed ovarian cancer (EU) Rituxan NHL faster infusion (US) Herceptin sc formulation HER2+ Actemra DMARD IR (US) Activase extend. time window AIS (US) Lucentis diabetic macular edema (US) Lucentis AMD 0.5 mg PRN (US)* Avastin mbc 2 nd line (EU) Avastin mcrc TML MabThera sc formulation (EU) Tarceva (US) NSCLC EGFR mutation 1 st line Actemra sc formulation Actemra RA DMARD IR H2H (EU) Actemra polyarticular JIA * New dosing regimen for already approved indication 27
28 2011: Three New Molecular Entities filed Expanding into selected therapeutic franchises Larger (> 1 bn) Smaller (up to ~1 bn) Oncology Neuroscience Metabolism Virology Immunology Zelboraf Erivedge pertuzumab T-DM1 GA101 GlyT-1 ocrelizumab MetMAb danoprevir mericitabine aleglitazar lebrikizumab Potential Filing Year Non risk-adjusted 28
29 Outlook for 2012 Sales growth (CER) Operational Excellence savings Core EPS growth target (CER) Dividend outlook Group & Pharma: low to mid-single digit Diagnostics: above market : CHF 2.4 bn* High single-digit Continue attractive dividend policy Barring unforeseen events; CER=Constant Exchange Rates; * vs. 2011: CHF 1.8 bn 29
30 We Innovate Healthcare 30
31 Group core operating profit and margin Strong margin increase over years 33.2% 34.9% 35.6% 38.0% +1.8 %p 1 (+0.7 %p) 39.9% 40.9% +2.1 %p 1 (+1.0 %p) % of sales CHF m 16,27216, % 1 (-9 %) 15,149 14,83614, % 1 (-9 %) 13, % 21.1% 22.4% +1.6 %p 1 (+1.3 %p) ,742 2, % 1 (-1 %) 2,178 1 CER = Constant Exchange Rates Roche Group Pharma Division Diagnostics Division 31
32 Roche: Staying focused on Prescription and Diagnostics Novartis 60% Merck & Co 90% Rx 1 OTC Vaccines Animal Health Generics Biosimilars Dx Others Ophthalmolog y Diversified Focused Pfizer 87% GSK 82% Sanofi Aventis 79% Bayer 31% Abbott 57% J&J 36% Generics/ EMs Generics/ EMs Eli Lilly 94% Branded Gx Intention AstraZeneca 100% Branded Gx Intention Roche 78% Amgen 100% BMS 100% Crop/Material Science Medical devices Medical devices 1 As of 2010 sales Source: FCMG; Company Annual Reports = Active Business Unit = Recent Transaction (post 2006) = Recent Transaction New Business Area (post 2006) 32
33 Roche: Focus on selected business/disease areas Aim to play in the lead Roche * 1 11 Novartis * Abbott Sanofi 4 6 Pfizer Merck JNJ AstraZeneca 5 Amgen 4 2 Sources: IMS MIDAS in PADDS; For Diagnostic: Industry Analyst Report; *Lucentis sold by Roche in US, by Novartis in RoW 33
Roche Committed to innovation and profitable growth. Dr. Nina Mojas Dr. Luis Correia Investor Relations Officers. Zurich, March 2012
Roche Committed to innovation and profitable growth Dr. Nina Mojas Dr. Luis Correia Investor Relations Officers Zurich, March 2012 1 This presentation contains certain forward-looking statements. These
More informationRoche: Committed to innovation and profitable growth. Dr. Alan Hippe, CFO Roche. London, November 2011
Roche: Committed to innovation and profitable growth Dr. Alan Hippe, CFO Roche London, November 2011 1 This presentation contains certain forward-looking statements. These forward-looking statements may
More informationRoche: Innovation & profitable growth Morningstar Management Behind the Moat Conference 9 November 2011
Roche: Innovation & profitable growth Morningstar Management Behind the Moat Conference 9 November 2011 Thomas Kudsk Larsen Head of Investor Relations North America This presentation contains certain forward-looking
More informationRoche: Committed to innovation and profitable growth. Severin Schwan, CEO Roche. Merrill Lynch, London September 2011
Roche: Committed to innovation and profitable growth Severin Schwan, CEO Roche Merrill Lynch, London September 2011 1 This presentation contains certain forward-looking statements. These forward-looking
More informationRoche: adapting to the changing environment. Severin Schwan, CEO Roche Group London, 15 September 2010
Roche: adapting to the changing environment Severin Schwan, CEO Roche Group London, 15 September 2010 This presentation contains certain forward-looking statements. These forward-looking statements may
More informationSustainable Profitable Growth through Innovation. Pascal Soriot Chief Operating Officer Roche Pharmaceuticals
1 Sustainable Profitable Growth through Innovation Pascal Soriot Chief Operating Officer Roche Pharmaceuticals 2 Q1 2009: A good start into the year 3 Q1 2010: High growth for both divisions Well above
More informationInnovation and Sustainability: An integrated approach
Innovation and Sustainability: An integrated approach Karl Mahler Head of Investor Relations Dianne Young Sustainability Communications Swiss Sustainability Leaders SRI Conference Zurich, 4 October 2013
More informationInnovation and growth
Innovation and growth Alan Hippe, CFO Roche Group JP Morgan Conference, January 2014 Performance update Industry in context Building pillars of innovation Building pillars of growth Summary 2 Group: Continued
More informationRoche Committed to Innovation. Sal. Oppenheim European Healthcare Investors Conference Frankfurt, September 2, 2008
Roche Committed to Innovation Sal. Oppenheim European Healthcare Investors Conference Frankfurt, September 2, 2008 This presentation contains certain forward-looking statements. These forward-looking statements
More informationCommitted to innovation and growth
This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates,
More informationMedical breakthroughs have always driven our business
1 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates,
More informationCommitted to innovation and growth
Committed to innovation and growth K. Mahler Investor Relations London, December 2012 Our strategy R&D and market dynamics Changing the standard of care Expanding in Emerging markets Summary An increasingly
More informationUniquely positioned for the future
Uniquely positioned for the future Severin Schwan, CEO Roche Group Bellevue meets Management Seminar, January 09 1 This presentation contains certain forward-looking statements. These forward-looking statements
More informationCommitted to innovation and growth
Committed to innovation and growth Alan Hippe, CFO Roche Group New York, February 2013 Premium for innovation Roche strategy: Focused on medically differentiated therapies Pharma Dia Regulators: Optimised
More informationOverview: The future of medicine is personalised. Severin Schwan, CEO
Overview: The future of medicine is personalised Severin Schwan, CEO This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes,
More informationUniquely positioned for the future. Severin Schwan, CEO Roche Group Merrill Lynch, London, 16 September 2008
Uniquely positioned for the future Severin Schwan, CEO Roche Group Merrill Lynch, London, 16 September 2008 1 This presentation contains certain forward-looking statements. These forward-looking statements
More informationImproving the standard of care
Improving the standard of care Alan Hippe CFO Roche London, November 2015 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such
More informationCommitted to innovation and growth Alan Hippe, CFO Roche Group
Committed to innovation and growth Alan Hippe, CFO Roche Group Jefferies Global Healthcare Conference 2012 November 14 th, 2012 This presentation contains certain forward-looking statements. These forward-looking
More informationBringing a successful partnership to the next level
Bringing a successful partnership to the next level Basle, 21 July 2008 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as
More informationErich Hunziker, Deputy Head of the Corporate Executive Committee and CFO
Roche: Navigating through rough seas JP Morgan Conference, January 2009 Erich Hunziker, Deputy Head of the Corporate Executive Committee and CFO This presentation contains certain forward-looking statements.
More informationRoche. Half year results July 21, 2011 London
1 Roche Half year results 2011 July 21, 2011 London 2 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects,
More informationRoche: Ensuring sustained success in a more challenging environment
Roche: Ensuring sustained success in a more challenging environment December 2010 Dr. Erich Hunziker, Deputy Head of the Corporate Executive Committee and CFO This presentation contains certain forward-looking
More informationRoche: Committed to innovation and profitable growth. Nina Goworek, Investor Relations Officer 10 November 2011
Roche: Committed to innovation and profitable growth Nina Goworek, Investor Relations Officer 10 November 2011 This presentation contains certain forward-looking statements. These forward-looking statements
More informationRoche: Driving sustainable growth
Roche: Driving sustainable growth Dr. Nicolas Dunant Investor Relations Officer, Roche Sal. Oppenheim Healthcare Conference, Frankfurt, 31 August 2009 This presentation contains certain forward-looking
More informationCommerzbank German Investment Seminar 2012
Commerzbank German Investment Seminar 2012 Matthias Zachert Chief Financial Officer New York, January 11, 2012 Agenda 1 The Merck Group 2 Key strengths 3 Unlocking value 4 Financials 5 Summary 2 Merck
More informationCheuvreux German Corporate Conference 2012
Cheuvreux German Corporate Conference 2012 Matthias Zachert Chief Financial Officer Frankfurt, January 17, 2012 Agenda 1 The Merck Group 2 Key strengths 3 Unlocking value 4 Financials 5 Summary 2 Merck
More informationTurning science into patient benefits
Turning science into patient benefits Severin Schwan, CEO Roche Group New York, May 2016 This presentation contains certain forward-looking statements. These forward-looking statements may be identified
More informationPersonalized healthcare: Fashion or substance?
Clinical Development at Roche: Driving the paradigm shift Jean-Jacques Garaud, MD Global Head Pharma Development, Chief Medical Officer Roche Sell sider breakfast Paris, October 23, 2008 Personalized healthcare:
More informationStrategic vision of Pharma Market
Strategic vision of Pharma Market Evolution 2012-2016 ACIP Presentation, Paris January 30, 2013 Introduction This presentation draws strategic orientations for pharma companies considering the expected
More informationInvestors/Analysts Conference London, July 2007 Ian Bishop
Investors/Analysts Conference London, July 2007 Ian Bishop This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects,
More informationJP Morgan Healthcare Conference Stefan Oschmann Head of Pharma. San Francisco, January 9, 2012
JP Morgan Healthcare Conference Stefan Oschmann Head of Pharma San Francisco, January 9, 2012 Disclaimer Remarks All comparative figures relate to the corresponding last year s period. From 2007 the Generics
More informationBIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS
: TECHNOLOGIES AND GLOBAL MARKETS BIO061C April 2014 Jackson Highsmith Project Analyst ISBN: 1-56965-801-3 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free within
More informationOperational Excellence Ensuring sustained success in a more challenging environment. Conference Call; 17 November 2010
Operational Excellence Ensuring sustained success in a more challenging environment Conference Call; 17 November 2010 This presentation contains certain forward-looking statements. These forward-looking
More informationPersonalized healthcare Getting from promise to reality
Personalized healthcare Getting from promise to reality Severin Schwan, CEO Roche Group Swiss-American Chamber of Commerce, 26 August 2009 1 Roche The challenge Personalised healhcare Implementation at
More informationImportant notice. 139 th Ordinary general meeting of shareholders. Christophe Weber President & Chief Executive Officer
139 th Ordinary general meeting of shareholders Christophe Weber President & Chief Executive Officer June 26, 2015 Important notice Forward-Looking Statements This presentation contains forward-looking
More informationCreating value for patients
2010 Roche Annual Report Creating value for patients Key figures Roche Group Index 2008 = 100 2010 2009 2008 Sales mchf 47,473 49,051 45,617 Free cash flow mchf 4,699 8,893 4,979 2010 2009 2008 Research
More informationBank of America Merrill Lynch Healthcare Conference. September 13, 2013
Bank of America Merrill Lynch Healthcare Conference September 13, 2013 Safe Harbor Statement This presentation contains forward-looking statements that are based on management s current expectations and
More informationQuo vadis Medical Industry?
Quo vadis Medical Industry? 18th December 2014 Karl Branzén Sweden has experienced the winds of change in the drug industry In the 70s and 80s Sweden had two big medical/drug corporations Pharmacia and
More informationImproving the standard of care
Improving the standard of care Bill Anderson Head of Global Product Strategy and Chief Marketing Officer London, September 2015 This presentation contains certain forward-looking statements. These forward-looking
More informationTranslating excellence in science into customer benefit an update on CNS portfolio
Translating excellence in science into customer benefit an update on CNS portfolio Karl Mahler, Head of Investor Relations Eugene Tierney, Global Product Strategy TA Head, CNS Performance update and strategy
More informationDatamonitor Healthcare Pharma intelligence informa Datamonitor Healthcare Content Calendar
Datamonitor Healthcare 2017 Datamonitor Healthcare Content Calendar 2017 Content Calendar Published February 2017 Datamonitor Healthcare provides up-to-date insights and analysis that you can trust. Disease
More informationRoche. New York City 7 December 2016
Roche Andrew C. Chan, M.D. Ph.D. Senior Vice President, Research Biology of Genentech Research and Early Development (gred) New York City 7 December 2016 This presentation contains certain forward-looking
More informationEXANE Conference. Jérôme Contamine, Executive Vice President, Chief Financial Officer. Paris June 13, 2017
EXANE Conference Jérôme Contamine, Executive Vice President, Chief Financial Officer Paris June 13, 2017 Forward Looking Statements This presentation contains forward-looking statements as defined in the
More informationCENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS
CENTRAL NERVOUS SYSTEM (CNS) : TECHNOLOGIES AND GLOBAL MARKETS BIO074C March 2016 Jackson Highsmith Project Analyst ISBN: 1-62296-246-X BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215
More informationImproving the standard of care
Improving the standard of care Severin Schwan, CEO Roche Group Bernstein Strategic Conference New York, May 2015 This presentation contains certain forward-looking statements. These forward-looking statements
More informationQuo vadis Medical Industry?
Quo vadis Medical Industry? 17th December 2015 Karl Branzén Sweden has experienced the winds of change in the drug industry u In the 70s and 80s Sweden had two big medical/drug corporations Pharmacia and
More informationJ.P. Morgan Health Care Conference
J.P. Morgan Health Care Conference Thomas C. Freyman Executive VP, Finance and CFO Abbott GDS_70000_Title_v1 1 Forward-Looking Statement Comments will be made that are forward-looking statements for the
More informationCommitted to innovation and growth Dr. Karl Mahler Head of Investor Relations
Committed to innovation and growth Dr. Karl Mahler Head of Investor Relations 5 th Annual Biosimilars Conference Sanford Bernstein December, 2012 This presentation contains certain forward-looking statements.
More informationDoing Now What Patients Need Next. Teppo Hyytiä 21 May 2015
Doing Now What Patients Need Next Teppo Hyytiä 21 May 2015 Roche Diagnostics Oy Future Diagnostics Symposium The Roche Group Our Company Strategy Our Innovation Pharmaceuticals Diagnostics Basic facts
More informationPersonalized Healthcare Diagnostik und Therapie aus einer Hand
Personalized Healthcare Diagnostik und Therapie aus einer Hand Priv.-Doz. Dr. med. Christian Meisel DVFA Life Science Conference, 17 June 2009 1 The Challenge Personalised healthcare Roche s unique position
More informationMylan. Raymond James 40 th Annual Institutional Investors Conference March 05, 2019
Mylan Raymond James 40 th Annual Institutional Investors Conference March 05, 2019 Forward-Looking Statements This presentation contains forward-looking statements. These statements are made pursuant to
More informationDeutsche Bank Healthcare Conference
Deutsche Bank Healthcare Conference Jérôme Contamine, Executive Vice President, Chief Financial Officer Boston May 4, 2017 Forward Looking Statements This presentation contains forward-looking statements
More informationImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2013 Financial Results and Provides Fiscal Year 2014 Financial Guidance and Corporate Update
August 2, 2013 ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2013 Financial Results and Provides Fiscal Year 2014 Financial Guidance and Corporate Update Kadcyla sales off to strong start. Decision
More informationUBS Global Life Sciences Conference
September 20, 2011 UBS Global Life Sciences Conference Tecan Group AG Dr. Rudolf Eugster, CFO September 20, 2011 / p2 / UBS GLSC Contents Introducing Tecan Strategic Growth Drivers Financials H1 2011 &
More informationBIOPHARMACEUTICAL BUSINESSES
BIOPHARMACEUTICAL BUSINESSES Our Biopharmaceuticals businesses consist of four patientcentric, customer-facing business units. The business units are responsible for further clinical development and lifecycle
More informationAnnual General Meeting Roche Holding Ltd 14 March 2017
Annual General Meeting Roche Holding Ltd 14 March 2017 Address by Christoph Franz Chairman of the Board of Directors (Check against delivery) Address Christoph Franz Page 2/10 Dear Shareholders, Ladies
More informationGoldman Sachs Key Debates In Biosimilars Conference
Goldman Sachs Key Debates In Biosimilars Conference Diem Nguyen Regional President North America, Global Established Pharmaceuticals April 2, 2015 1 2 Forward Looking Statements Our discussions during
More informationPhylogica. Harnessing Biodiversity for Peptide Therapies. Life Sciences Showcase, 23 August 2011 Nick Woolf: CFO & VP Corporate Development
Phylogica Harnessing Biodiversity for Peptide Therapies Life Sciences Showcase, 23 August 2011 Nick Woolf: CFO & VP Corporate Development Introduction Biotech company offering leading peptide drug discovery
More informationGENENTECH PROVIDES UPDATE ON PIPELINE AGENTS AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY MEETING
NEWS RELEASE Media Contact: Krysta Pellegrino (650) 225-8226 Investor Contact: Diane Schrick (650) 225-1599 Advocacy Contact: Kristin Reed (650) 467-9831 GENENTECH PROVIDES UPDATE ON PIPELINE AGENTS AT
More informationPersonalized Medicine A new challenge for applied human pharmacology?
Personalized Medicine A new challenge for applied human pharmacology? Jochen Theis, MD FFPM InHeCon Leipzig 2 nd March 2012 Personalized Medicine: Predicting Variability in Drug Response InHeCon Jochen
More information35 th Annual J.P. Morgan Healthcare Conference. Gwan Sun Lee. President & CEO
35 th Annual J.P. Morgan Healthcare Conference Gwan Sun Lee President & CEO This presentation contains forward-looking statements with respect to the financial condition, results of operations and businesses
More informationEli Lilly and Company
Eli Lilly and Company Acquisition of ImClone Systems, Inc. October 6 th, 2008 SEC Disclosure During this conference call, we anticipate making projections and forward-looking statements that are based
More informationAdam Schechter President, Global Human Health. Merck & Co., Inc. Cowen 2015 Healthcare Conference. March 3, 2015
Adam Schechter President, Global Human Health Merck & Co., Inc. Cowen 2015 Healthcare Conference March 3, 2015 Forward-Looking Statement This communication includes forward-looking statements within the
More informationAnnual General Meeting Roche Holding Ltd 6 March 2012
r Annual General Meeting Roche Holding Ltd 6 March 2012 Address by Franz B. Humer Chairman of the Board of Directors (Check against delivery.) Address by Franz B. Humer Page 2/12 Dear Shareholders, Ladies
More informationOctober 23+24, Dr. Axel Herberg, CEO
Gerresheimer: Excellent prospects as a unique supplier to the Pharma & Life Science Industry Gerresheimer Capital Markets Day October 23+24, 2008 Dr. Axel Herberg, CEO 0 Disclaimer This presentation may
More informationHealth Care Worldwide. Crédit Suisse Global Credit Products Conference October 1, Barcelona
Health Care Worldwide Crédit Suisse Global Credit Products Conference October 1, 2015 - Barcelona Safe Harbor Statement This presentation contains forward-looking statements that are subject to various
More informationRecent Trends in Companion Diagnostic Test Development Partnerships
Recent Trends in Companion Diagnostic Test Development Partnerships Andrew S. Thompson, PhD, Director of Therapy and Analysis, GlobalData Medical, London Tyler Fletcher, Global Head, GlobalData Medical,
More informationAnnual General Meeting Roche Holding Ltd 13 March 2018
Annual General Meeting Roche Holding Ltd 13 March 2018 Address by Christoph Franz Chairman of the Board of Directors (Check against delivery) Address by Christoph Franz page 2/12 Dear Shareholders, Ladies
More informationValuation of Biosimilar and Key Value Drivers Dr. Patrik Frei October 2015 Biosimilars Asia
Valuation of Biosimilar and Key Value Drivers Dr. Patrik Frei October 0 Biosimilars Asia Agenda Introduction Valuation of Biosimilar Key Value Driver / Conclusion Venture Valuation Independent assessment
More informationProgram Coordinator Medication Assistance Program Smilow Cancer Hospital at Yale New Haven
Program Coordinator Medication Assistance Program Smilow Cancer Hospital at Yale New Haven Yale MAP Program Consists of 5 FTE s Has been established for five years Was originally mirrored from the Ohio
More informationThe Evolving Role Of Prescription Benefit Managers
The Evolving Role Of Prescription Benefit Managers Steve Miller, MD Senior Vice President & Chief Medical Officer November 1, 2016 1 Prescription drugs: A growing share of U.S. healthcare spend Net spending
More informationCORPORATE PRESENTATION January 2019
CORPORATE PRESENTATION January 2019 1 DISCLAIMER This presentation contains forward-looking statements about Outlook Therapeutics, Inc. ( Outlook Therapeutics or the Company ) based on management s current
More informationScientific Excellence Transforming Medical Treatment
Scientific Excellence Transforming Medical Treatment Genentech Research and Early Development as an Experiment in R&D Productivity Karl Mahler - Head of Investor Relations Sean Bohen - Senior Vice President,
More informationSample Pages. Companion Diagnostics Market,
Sample Pages Companion Diagnostics Market, 2012-2023 This page is intentionally left blank Copyright 2013 Roots Analysis Private Ltd. All rights reserved. No part of this report should be copied or reproduced
More informationGlobal Pharmaceutical Industry Profile 2012
2012 1. Global Pharmaceuticals Market 1.1 Pharmaceutical Sector (Market) Performance The global pharmaceutical market has shown steady growth throughout the years. In particular, the market size of the
More informationMoving from volume to value in the generic business model
Moving from volume to value in the generic business model CPhI Pre-connect conference Frankfurt 23rd October 2017 Copyright 2016 QuintilesIMS. All rights reserved. Key drivers to 2021 Global growth moderating
More informationComparison of the Non-patent Drug Exclusivities Available in the United States, Canada, Europe and Japan
Comparison of the Non-patent Drug Exclusivities Available in the United States, Canada, Europe and Japan The International Economic Forum of the Americas Serge Lapointe, Ph.D. Partner, Patent Agent June
More informationTeva Pharmaceutical Industries Ltd. J.P. Morgan Healthcare Conference. Kåre Schultz President and CEO January 7, 2019
Teva Pharmaceutical Industries Ltd. J.P. Morgan Healthcare Conference Kåre Schultz President and CEO January 7, 2019 Cautionary Note Regarding Forward-Looking Statements 2 This presentation contains forward-looking
More informationJ.P. Morgan Healthcare Conference
J.P. Morgan Healthcare Conference Michael Severino Vice Chairman and President January 9, 2019 Forward-Looking Statements and Non-GAAP Financial Information Some statements in this presentation are, or
More informationRoche in Australia Innovation Leader
Roche in Australia Innovation Leader About Roche Innovation: it s in our DNA 7,000,874 hours of work 6,587 experiments 423 researchers 1 drug For nearly 120 years, Roche has been committed to improving
More informationJefferies 2016 Healthcare Conference. June 8, 2016
Jefferies 2016 Healthcare Conference June 8, 2016 Safe Harbor This presentation contains forward looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities
More informationNews For Immediate Release
News For Immediate Release Contact: Gary Gatyas IMS Institute for Healthcare Informatics (610) 244-2600 ggatyas@us.imshealth.com IMS Study Forecasts Rebound in Global Spending on Medicines, Reaching Nearly
More informationBIOTECHNOLOGY IN EUROPE: KEY TRENDS
BIOTECHNOLOGY IN EUROPE: KEY TRENDS Eva Edery, Senior Principal, IMS Health Global Pharma Strategy EGA Symposium on Biosimilars, London, May 27 Agenda Global pharmaceutical trends Biotech market dynamics
More informationBiomanufacturing Capacity for Biosimilars: Is there enough?
Biomanufacturing Capacity for Biosimilars: Is there enough? Cambridge Healthtech Institute s Third Annual BIOAnalytical Summit 2012 Mar 19-22 Baltimore, MD BioProcess Technology Consultants www.bptc.com
More informationAt the Forefront of R&D Innovation and Breakthrough Treatments
Patient images At the Forefront of R&D Innovation and Breakthrough Treatments Michael Varney, Ph.D. Executive Vice President, Genentech Research and Early Development Member of Roche Corporate Executive
More informationJefferies Health Care Seminar New York, June 3, Maris Hartmanis President & CEO
Jefferies Health Care Seminar New York, June 3, 2014 Maris Hartmanis President & CEO 2 Medivir The emerging European pharma company Headquartered and listed in Stockholm, Sweden ~ 140 employees, of which
More informationInnovating Antibodies, Improving Lives. 37 th Annual J.P. Morgan Healthcare Conference January 9, 2019
Innovating Antibodies, Improving Lives 37 th Annual J.P. Morgan Healthcare Conference January 9, 2019 Forward Looking Statement This presentation contains forward looking statements. The words believe,
More informationAcquisition of CaridianBCT Holding Corp.
Press Conference & Analyst Meeting Acquisition of CaridianBCT Holding Corp. Terumo Corporation March 7, 2011 Summary of Acquisition Target Company: CaridianBCT Holding Corp. (US) Seller Company: Purchase
More informationRoche, Roche Molecular Diagnostics and more
, Molecular and more [Monte Wetzel, PhD] Patients have questions. We provide answers. Group Clear focus on Healthcare Innovation with two strong pillars Pharma Pharma Genentech Chugai Molecular Professional
More informationVISION & STRATEGY FIC LIC. Interview with the President
VISION & STRATEGY Interview with the President A conversation with Isao Teshirogi, President and CEO about the Shionogi Growth Strategy 2020 (SGS2020) VISION & STRATEGY SGS2020 Growth Strategies Under
More informationQIAGEN Sample & Assay Technologies From Discovery to Patient
QIAGEN From Discovery to Patient New York, February 14 QIAGEN 2008 Analyst & Investor Day Peer Schatz, CEO -7- Forward Looking Statements Safe Harbor Statement: Certain of the statements contained in this
More informationBiotech Showcase 2016
1 Biotech Showcase 2016 Our Value Proposition Advancing broad product pipeline of biosimilars and next generation antibody therapeutics Proven track record in superior quality, efficient R&D and manufacturing
More informationCompany Profile. German-Taiwan Biotech Seminar 6 November 2017
Company Profile German-Taiwan Biotech Seminar 6 November 2017 Our Mission Bayer: Science For A Better Life A growing and aging world population requires an adequate supply of food and improved medical
More informationHealth Care Worldwide. Bank of America, 2007 Health Care Conference, May 30, 2007
Health Care Worldwide Bank of America, 2007 Health Care Conference, May 30, 2007 1 Fresenius This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future
More informationPersonalised Healthcare Solutions (PHCS) Excellence for your Biomarker-driven Strategies
Personalised Healthcare Solutions (PHCS) Excellence for your Biomarker-driven Strategies The value of In Vitro Diagnostics The value of diagnostics as an integral part in the healthcare value chain Diagnostics
More informationRoche Annual Report We Innovate Healthcare. Because every life counts.
Roche Annual Report 2008 We Innovate Healthcare. Because every life counts. Key figures Roche Group Index 2006 = 100 2008 2007 2006 Sales mchf 45,617 46,133 42,041 Equity ratio % 70.7 68.2 62.9 2008 2007
More informationEngage with us on Twitter: #Molecule2Miracle
Engage with us on Twitter: #Molecule2Miracle Kassy Perry President & CEO Perry Communications Group PhRMA Alliance Development Consultant.@kassyperry Emily Burke, Ph.D. Director of Curriculum BioTech
More information2006 Half Year Financial Results. July 27, 2006
2006 Half Year Financial Results July 27, 2006 Agenda Introduction Roch Doliveux CNS Allergy Inflammation R&D Day H1 2006 Financial Results Luc Missorten FY 2006 Outlook Conclusion Roch Doliveux A Global
More informationStratified Medicines and Companion Diagnostics
Stratified Medicines and Companion Diagnostics An Industry Viewpoint 2 nd May 2013 Eddie Blair Managing Director Integrated Medicines www.integratedmedicines.co.uk eddie.blair@integratedmedicines.co.uk
More information